Home ›  Medical Devices ›  Report Detail

Global Physician Survey on Stents, Stent-Grafts and Vulnerable Plaque Treatment 2011

Published: January 2011
No. of Pages: 307
  

This report details the responses of a comprehensive survey conducted of interventional cardiologists, interventional radiologists and cardiac surgeons on product preferences, placement techniques and trends in the use of drug eluting and bare metal stents, bifurcated stents, bioabsorbable stents, stent grafts, vulnerable plaque diagnosis and treatment and endovascular imaging technologies. The Global Physician Survey on Stents, Stent-Grafts and Endovascular Imaging includes:

• The United States
• Europe
• Asia-Pacific
• Latin America
• Middle East
• Africa

This report covers:

• Number and Type of Stents Placed
• Type of Endovascular Imaging Used
• Bifurcated Stents and Their Use
• Most Important Benefit When Using Bifurcated Stents
• Preferred Bifurcated Stent Alternative
• Bioabsorbable Stents and Their Use
• Most Important Benefit When Using Bioabsorbable Stents
• Most Important Bioabsorable Stent Drawback
• Most Important Drug-Eluting Stent Concern
• Most Effective Drug-Eluting Stent Drug for Combating Restenosis
• Stent-Graft Brand Preference
• Most Important Construction Feature for Stent-Grafts
• Most Important Design Feature for Next Generation Stent-Grafts
• The Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts
• Concerns about the Use of TAA Stent-Grafts

Global Physician Survey on Stents, Stent-Grafts and Vulnerable Plaque Treatment 2011

TABLE OF CONTENTS

LIST OF FIGURES

LIST OF CHARTS

EXECUTIVE SUMMARY

  • 1.1 SURVEY OVERVIEW
  • 1.2 CORONARY AND PERIPHERAL STENTS
  • 1.3 ENDOVASCULAR IMAGING TECHNOLOGY
  • 1.4 BIFURCATED STENT BENEFITS AND DRAWBACKS
  • 1.5 ALTERNATIVES TO BIFURCATED STENTS
  • 1.6 BIOABSORBABLE STENT BENEFITS AND DRAWBACKS
  • 1.7 DRUG-ELUTING STENTS
  • 1.8 IMPORTANT STENT-GRAFT CONSTRUCTION FEATURES
  • 1.9 STENT-GRAFT BRAND PREFERENCE
  • 1.10 THORACIC ABDOMINAL ANEURYSM STENT-GRAFTS
  • 1.11 VULNERABLE PLAQUE SCREENING
  • 1.12 VULNERABLE PLAQUE TREATMENT
  • 1.13 LIST OF COUNTRIES AND TOPICS

SURVEY HIGHLIGHTS

  • 2.1 RESPONDENT CHARACTERISTICS
  • 2.2 RESPONSE SUMMARY

RESEARCH METHODOLOGY

  • 3.1 RESEARCH SCOPE

GLOBAL STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

  • 4.1 INTRODUCTION
    • 4.1.1 Bioabsorbable Stents
    • 4.1.2 Bifurcated Stents
    • 4.1.3 Stent-Grafts
    • 4.1.4 Vulnerable Plaque
  • 4.2 GLOBAL OVERVIEW FOR STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE
    • 4.2.1 Geographical Distribution
    • 4.2.2 Respondent Specialty
    • 4.2.3 Number and Type of Stents Placed
    • 4.2.4 Type of Endovascular Imaging Used
    • 4.2.5 Bifurcated Stents and Their Use
    • 4.2.6 Most Important Benefit of Bifurcated Stents
    • 4.2.7 Most Important Bifurcated Stent Drawback
    • 4.2.8 Preferred Bifurcated Stent Alternatives
    • 4.2.9 Bioabsorbable Stents and Their Use
    • 4.2.10 Most Important Bioabsorbable Stent Benefit
    • 4.2.11 Most Important Bioabsorbable Stent Drawback
    • 4.2.12 Most Important Drug-Eluting Stent Concern
    • 4.2.13 Most Effective Drug-Eluting Stent Drug for Combating Restenosis
    • 4.2.14 Stent-Graft Brand Preference
    • 4.2.15 Most Important Construction Feature for Stent-Grafts
    • 4.2.16 Most Important Design Feature for Next-Generation Stent-Grafts
    • 4.2.17 The Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts
    • 4.2.18 Concerns about the Use of TAA Stent-Grafts
    • 4.2.19 Most Promising Vulnerable Plaque Screening Technology
    • 4.2.20 Most Promising Vulnerable Plaque Treatment Technology

U.S. STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

  • 5.1 GEOGRAPHICAL DISTRIBUTION
  • 5.2 RESPONDENT SPECIALTY
  • 5.3 NUMBER AND TYPE OF STENTS PLACED
  • 5.4 TYPE OF ENDOVASCULAR IMAGING USED
  • 5.5 BIFURCATED STENTS AND THEIR USE
  • 5.6 MOST IMPORTANT BENEFIT WHEN USING BIFURCATED STENTS
  • 5.7 DRAWBACKS TO THE USE OF BIFURCATED STENTS
  • 5.8 PREFERRED BIFURCATED STENT ALTERNATIVES
    • 5.8.1 Preferred Bifurcated Stent Alternatives by Specialty
  • 5.9 BIOABSORBABLE STENTS AND THEIR USE
  • 5.10 MOST IMPORTANT BENEFIT WHEN USING BIOABSORBABLE STENTS
  • 5.11 MOST IMPORTANT BIOABSORBABLE STENT DRAWBACK
  • 5.12 MOST IMPORTANT DRUG-ELUTING STENT CONCERN
  • 5.13 MOST EFFECTIVE DRUG-ELUTING STENT DRUG FOR COMBATING RESTENOSIS
    • 5.13.1 Most Effective Drug-Eluting Stent Drug for Combating Restenosis by Specialty
  • 5.14 PREFERRED BRAND OF STENT-GRAFT
  • 5.15 MOST IMPORTANT CONSTRUCTION FEATURE FOR STENT-GRAFTS
  • 5.16 MOST IMPORTANT DESIGN FEATURE FOR NEXT-GENERATION STENT-GRAFTS
  • 5.17 THE USE OF THORACIC AORTIC ANEURYSM STENT-GRAFTS
  • 5.18 CONCERNS ABOUT THE USE OF TAA STENT-GRAFTS
  • 5.19 MOST PROMISING VULNERABLE PLAQUE SCREENING TECHNOLOGY
    • 5.19.1 Most Promising Vulnerable Plaque Screening Technology by Specialty
  • 5.20 MOST PROMISING VULNERABLE PLAQUE TREATMENT TECHNOLOGY
    • 5.20.1 Most Promising Vulnerable Plaque Treatment Technology by Specialty

EUROPEAN STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

  • 6.1 GEOGRAPHICAL DISTRIBUTION
  • 6.2 RESPONDENT SPECIALTY
  • 6.3 NUMBER AND TYPE OF STENTS PLACED
  • 6.4 TYPE OF ENDOVASCULAR IMAGING USED
  • 6.5 BIFURCATED STENTS AND THEIR USE
  • 6.6 MOST IMPORTANT BENEFIT WHEN USING BIFURCATED STENTS
  • 6.7 DRAWBACKS TO THE USE OF BIFURCATED STENTS
  • 6.8 PREFERRED BIFURCATED STENT ALTERNATIVES
    • 6.8.1 Preferred Bifurcated Stent Alternatives by Specialty
  • 6.9 BIOABSORBABLE STENTS AND THEIR USE
  • 6.10 MOST IMPORTANT BENEFIT WHEN USING BIOABSORBABLE STENTS
  • 6.11 MOST IMPORTANT BIOABSORBABLE STENT DRAWBACK
  • 6.12 MOST IMPORTANT DRUG-ELUTING STENT CONCERN
  • 6.13 MOST EFFECTIVE DRUG-ELUTING STENT DRUG FOR COMBATING RESTENOSIS
    • 6.13.1 Most Effective Drug-Eluting Stent Drug for Combating Restenosis by Specialty
  • 6.14 PREFERRED BRAND OF STENT-GRAFT
  • 6.15 MOST IMPORTANT CONSTRUCTION FEATURE FOR STENT-GRAFTS
  • 6.16 MOST IMPORTANT DESIGN FEATURE FOR NEXT-GENERATION STENT-GRAFTS
  • 6.17 THE USE OF THORACIC AORTIC ANEURYSM (TAA) STENT-GRAFTS
  • 6.18 CONCERNS ABOUT THE USE OF TAA STENT-GRAFTS
  • 6.19 MOST PROMISING VULNERABLE PLAQUE SCREENING TECHNOLOGY
    • 6.19.1 Most Promising Vulnerable Plaque Screening Technology by Specialty
  • 6.20 MOST PROMISING VULNERABLE PLAQUE TREATMENT TECHNOLOGY

LATIN AMERICAN STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

  • 7.1 GEOGRAPHICAL DISTRIBUTION
  • 7.2 RESPONDENT SPECIALTY
  • 7.3 NUMBER AND TYPE OF STENTS PLACED
  • 7.4 TYPE OF ENDOVASCULAR IMAGING USED
  • 7.4.1 Imaging Technology Preference by Country
  • 7.5 BIFURCATED STENTS AND THEIR USE
  • 7.6 MOST IMPORTANT BENEFIT WHEN USING BIFURCATED STENTS
  • 7.7 DRAWBACKS TO THE USE OF BIFURCATED STENTS
  • 7.8 PREFERRED BIFURCATED STENT ALTERNATIVES
  • 7.9 BIOABSORBABLE STENTS AND THEIR USE
  • 7.10 MOST IMPORTANT BENEFIT WHEN USING BIOABSORBABLE STENTS
  • 7.11 MOST IMPORTANT BIOABSORBABLE STENT DRAWBACK
  • 7.12 MOST IMPORTANT DRUG-ELUTING STENT CONCERN
  • 7.13 MOST EFFECTIVE DRUG-ELUTING STENT DRUG FOR COMBATING RESTENOSIS
  • 7.14 PREFERRED BRAND OF STENT-GRAFT
  • 7.15 MOST IMPORTANT CONSTRUCTION FEATURE FOR STENT-GRAFTS
  • 7.16 MOST IMPORTANT DESIGN FEATURE FOR NEXT-GENERATION STENT-GRAFTS
  • 7.17 THE USE OF THORACIC AORTIC ANEURYSM (TAA) STENT-GRAFTS
  • 7.18 CONCERNS ABOUT THE USE OF TAA STENT-GRAFTS
  • 7.19 MOST PROMISING VULNERABLE PLAQUE SCREENING TECHNOLOGY
  • 7.20 MOST PROMISING VULNERABLE PLAQUE TREATMENT TECHNOLOGY

ASIA-PACIFIC STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

  • 8.1 GEOGRAPHICAL DISTRIBUTION
  • 8.2 RESPONDENT SPECIALTY
  • 8.3 NUMBER AND TYPE OF STENTS PLACED
  • 8.4 TYPE OF ENDOVASCULAR IMAGING USED
  • 8.4.1 Imaging Technology Preference by Country
  • 8.5 BIFURCATED STENTS AND THEIR USE
  • 8.6 MOST IMPORTANT BENEFIT WHEN USING BIFURCATED STENTS
  • 8.7 DRAWBACKS TO THE USE OF BIFURCATED STENTS
  • 8.8 PREFERRED BIFURCATED STENT ALTERNATIVES
  • 8.9 BIOABSORBABLE STENTS AND THEIR USE
  • 8.10 MOST IMPORTANT BENEFIT WHEN USING BIOABSORBABLE STENTS
  • 8.11 MOST IMPORTANT BIOABSORBABLE STENT DRAWBACK
  • 8.12 MOST IMPORTANT DRUG-ELUTING STENT CONCERN
  • 8.13 MOST EFFECTIVE DRUG-ELUTING STENT DRUG FOR COMBATING RESTENOSIS
  • 8.14 PREFERRED BRAND OF STENT-GRAFT
  • 8.15 MOST IMPORTANT CONSTRUCTION FEATURE FOR STENT-GRAFTS
  • 8.16 MOST IMPORTANT DESIGN FEATURE FOR NEXT-GENERATION STENT-GRAFTS
  • 8.17 THE USE OF THORACIC AORTIC ANEURYSM (TAA) STENT-GRAFTS
  • 8.18 CONCERNS ABOUT THE USE OF TAA STENT-GRAFTS
  • 8.19 MOST PROMISING VULNERABLE PLAQUE SCREENING TECHNOLOGY
  • 8.20 MOST PROMISING VULNERABLE PLAQUE TREATMENT TECHNOLOGY

MIDDLE EASTERN AND AFRICAN STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

  • 9.1 GEOGRAPHICAL DISTRIBUTION
  • 9.2 RESPONDENT SPECIALTY
  • 9.3 NUMBER AND TYPE OF STENTS PLACED
  • 9.4 TYPE OF ENDOVASCULAR IMAGING USED
    • 9.4.1 Imaging Technology Preference by Country
  • 9.5 BIFURCATED STENTS AND THEIR USE
  • 9.6 MOST IMPORTANT BENEFIT WHEN USING BIFURCATED STENTS
  • 9.7 DRAWBACKS TO THE USE OF BIFURCATED STENTS
  • 9.8 PREFERRED BIFURCATED STENT ALTERNATIVES
  • 9.9 BIOABSORBABLE STENTS AND THEIR USE
  • 9.10 MOST IMPORTANT BENEFIT WHEN USING BIOABSORBABLE STENTS
  • 9.11 MOST IMPORTANT BIOABSORBABLE STENT DRAWBACK
  • 9.12 MOST IMPORTANT DRUG-ELUTING STENT CONCERN
  • 9.13 MOST EFFECTIVE DRUG-ELUTING STENT DRUG FOR COMBATING RESTENOSIS
  • 9.14 PREFERRED BRAND OF STENT-GRAFT
  • 9.15 MOST IMPORTANT CONSTRUCTION FEATURE FOR STENT-GRAFTS
  • 9.16 MOST IMPORTANT DESIGN FEATURE FOR NEXT-GENERATION STENT-GRAFTS
  • 9.17 THE USE OF THORACIC AORTIC ANEURYSM (TAA) STENT-GRAFTS
  • 9.18 CONCERNS ABOUT THE USE OF TAA STENT-GRAFTS
  • 9.19 MOST PROMISING VULNERABLE PLAQUE SCREENING TECHNOLOGY
  • 9.20 MOST PROMISING VULNERABLE PLAQUE TREATMENT TECHNOLOGY

ABBREVIATIONS

APPENDIX

  • 11.1 GEOGRAPHIC DISTRIBUTION OF RESPONSES
  • 11.2 TECHNIQUES FOR STENTING BIFURCATED LESIONS
  • 11.3 SAMPLE SURVEY

LIST OF FIGURES

EXECUTIVE SUMMARY

SURVEY HIGHLIGHTS

  • Figure 2-1: Respondent Characteristics, Stents, Stent-Grafts and Vulnerable Plaque, 2010
  • Figure 2-2: Respondent Characteristics, Stents, Stent-Grafts and Vulnerable Plaque, 2010

RESEARCH METHODOLOGY

GLOBAL STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

  • Figure 4-1: Geographical Distribution, Global Respondents, 2010
  • Figure 4-2: Respondent Specialty, Global Responses, 2010
  • Figure 4-3: Coronary and Peripheral Stents Placed per Month, Global Responses, 2010
  • Figure 4-4: Imaging Technology Preferences, Percentage of Use for Respondents, Global Responses, 2010
  • Figure 4-5: Imaging Technology Preferences for Endovascular Procedures, Global Responses, 2010
  • Figure 4-6: Bifurcated Stents and Their Use, Global Responses, 2010
  • Figure 4-7: Most Important Bifurcated Stent Benefit, Global Responses, 2010
  • Figure 4-8: Most Important Bifurcated Stent Drawback, Global Responses, 2010
  • Figure 4-9: Preferred Bifurcated Stent Alternatives, Global Responses, 2010 (Part 1 of 2)
  • Figure 4-10: Preferred Bifurcated Stent Alternatives, Global Responses, 2010 (Part 2 of 2)
  • Figure 4-11: Bioabsorbable Stents and Their Use, Global Responses, 2010
  • Figure 4-12: Most Important Bioabsorbable Stent Benefit, Global Responses, 2010 (Part 1 of 2)
  • Figure 4-13: Most Important Bioabsorbable Stent Benefit, Global Responses, 2010 (Part 2 of 2)
  • Figure 4-14: Most Important Bioabsorbable Stent Drawback, Global Responses, 2010
  • Figure 4-15: Most Important Drug-Eluting Stent Concern, Global Responses, 2010
  • Figure 4-16: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Global Responses, 2010
  • Figure 4-17: Stent-Graft Brand Preference, Global Responses, 2010 (Part 1 of 2)
  • Figure 4-18: Stent-Graft Brand Preference, Global Responses, 2010 (Part 2 of 2)
  • Figure 4-19: Most Important Construction Feature for Stent-Grafts, Global Responses, 2010 (Part 1 of 2)
  • Figure 4-20: Most Important Construction Feature for Stent-Grafts, Global Responses, 2010 (Part 2 of 2)
  • Figure 4-21: Most Important Design Feature for Next-Generation Stent-Grafts, Global Responses, 2010
  • Figure 4-22: The Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts, Global Responses, 2010
  • Figure 4-23: Concerns about the Use of TAA Stent-Grafts, Global Responses, 2010 (Part 1 of 2)
  • Figure 4-24: Concerns about the Use of TAA Stent-Grafts, Global Responses, 2010 (Part 2 of 2)
  • Figure 4-25: Most Promising Vulnerable Plaque Screening Technology, Global Responses, 2010 (Part 1 of 2)
  • Figure 4-26: Most Promising Vulnerable Plaque Screening Technology, Global Responses, 2010 (Part 2 of 2)
  • Figure 4-27: Most Promising Vulnerable Plaque Treatment Technology, Global Responses, 2010

U.S. STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

  • Figure 5-1: Distribution of Survey Respondents by Geographic Region, U.S. Responses, 2010
  • Figure 5-2: Distribution of Survey Respondents by Specialty, U.S. Responses, 2010
  • Figure 5-3: Number and Type of Stents Placed, U.S. Responses, 2010
  • Figure 5-4: Type of Medical Imaging Used for Endovascular Procedures, U.S. Responses, 2010
  • Figure 5-5: Type of Medical Imaging Used for Endovascular Procedures by Specialty, U.S. Responses, 2010
  • Figure 5-6: Bifurcated Stents and Their Use, U.S. Responses, 2010
  • Figure 5-7: Most Important Benefit When Using Bifurcated Stents, U.S. Responses, 2010
  • Figure 5-8: Drawbacks to the Use of Bifurcated Stents, U.S. Responses, 2010
  • Figure 5-9: Preferred Bifurcated Stent Alternatives, U.S. Responses, 2010
  • Figure 5-10: Preferred Bifurcated Stent Alternatives by Specialty, U.S. Responses, 2010
  • Figure 5-11: Bioabsorbable Stents and Their Use, U.S. Responses, 2010
  • Figure 5-12: Most Important Benefit When Using Bioabsorbable Stents, U.S. Responses, 2010
  • Figure 5-13: Most Important Bioabsorbable Stent Drawback, U.S. Responses, 2010
  • Figure 5-14: Most Important Drug-Eluting Stent Concern, U.S. Responses, 2010
  • Figure 5-15: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, U.S. Responses, 2010
  • Figure 5-16: Most Effective Drug-Eluting Stent Drug for Combating Restenosis by Specialty, U.S. Responses, 2010
  • Figure 5-17: Preferred Brand of Stent-Graft, U.S. Responses, 2010
  • Figure 5-18: Most Important Construction Feature for Stent-Grafts, U.S. Responses, 2010
  • Figure 5-19: Most Important Design Feature for Next-Generation Stent-Grafts, U.S. Responses, 2010
  • Figure 5-20: Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts, U.S. Responses, 2010
  • Figure 5-21: Concerns about the Use of TAA Stent-Grafts, U.S. Responses, 2010
  • Figure 5-22: Most Promising Vulnerable Plaque Screening Technology, U.S. Responses, 2010
  • Figure 5-23: Most Promising Vulnerable Plaque Screening Technology by Specialty, U.S. Responses, 2010 (Part 1 of 2)
  • Figure 5-24: Most Promising Vulnerable Plaque Screening Technology by Specialty, U.S. Responses, 2010 (Part 2 of 2)
  • Figure 5-25: Most Promising Vulnerable Plaque Treatment Technology, U.S. Responses, 2010
  • Figure 5-26: Most Promising Vulnerable Plaque Treatment Technology by Specialty, U.S. Responses, 2010

EUROPEAN STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

  • Figure 6-1: Distribution of Survey Respondents by Geographic Region, European Responses, 2010
  • Figure 6-2: Distribution of Survey Respondents by Specialty, European Responses, 2010
  • Figure 6-3: Number and Type of Stents Placed Per Month, European Responses, 2010
  • Figure 6-4: Type of Medical Imaging Used for Endovascular Procedures, European Responses, 2010
  • Figure 6-5: Type of Medical Imaging Used for Endovascular Procedures by Specialty, European Responses, 2010
  • Figure 6-6: Bifurcated Stents and Their Use, European Responses, 2010
  • Figure 6-7: Most Important Benefit When Using Bifurcated Stents, European Responses, 2010
  • Figure 6-8: Drawbacks to the Use of Bifurcated Stents, European Responses, 2010
  • Figure 6-9: Preferred Bifurcated Stent Alternatives, European Responses, 2010
  • Figure 6-10: Preferred Bifurcated Stent Alternatives by Specialty, European Responses, 2010
  • Figure 6-11: Bioabsorbable Stents and Their Use, European Responses, 2010
  • Figure 6-12: Most Important Benefit When Using Bioabsorbable Stents, European Responses, 2010
  • Figure 6-13: Most Important Bioabsorbable Stent Drawback, European Responses, 2010
  • Figure 6-14: Most Important Drug-Eluting Stent Concern, European Responses, 2010
  • Figure 6-15: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, European Responses, 2010
  • Figure 6-16: Most Effective Drug-Eluting Stent Drug for Combating Restenosis by Specialty, European Responses, 2010
  • Figure 6-17: Preferred Brand of Stent-Graft, European Responses, 2010
  • Figure 6-18: Most Important Construction Feature for Stent-Grafts, European Responses, 2010
  • Figure 6-19: Most Important Design Feature for Next-Generation Stent-Grafts, European Responses, 2010
  • Figure 6-20: Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts, European Responses, 2010
  • Figure 6-21: Concerns about the Use of TAA Stent-Grafts, European Responses, 2010
  • Figure 6-22: Most Promising Vulnerable Plaque Screening Technology, European Responses, 2010
  • Figure 6-23: Most Promising Vulnerable Plaque Screening Technology by Specialty, European Responses, 2010
  • Figure 6-24: Most Promising Vulnerable Plaque Treatment Technology, European Responses, 2010

LATIN AMERICAN STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

  • Figure 7-1: Distribution of Survey Respondents by Geographic Region, Latin American Responses, 2010
  • Figure 7-2: Number and Type of Stents Placed per Month, Latin American Responses, 2010
  • Figure 7-3: Type of Medical Imaging Used for Endovascular Procedures, Latin American Responses, 2010
  • Figure 7-4: Type of Medical Imaging Used for Endovascular Procedures by Country, Latin American Responses, 2010
  • Figure 7-5: Bifurcated Stents and Their Use, Latin American Responses, 2010
  • Figure 7-6: Most Important Benefit When Using Bifurcated Stents, Latin American Responses, 2010
  • Figure 7-7: Drawbacks to the Use of Bifurcated Stents, Latin American Responses, 2010
  • Figure 7-8: Preferred Bifurcated Stent Alternatives, Latin American Responses, 2010
  • Figure 7-9: Bioabsorbable Stents and Their Use, Latin American Responses, 2010
  • Figure 7-10: Most Important Benefit When Using Bioabsorbable Stents, Latin American Responses, 2010
  • Figure 7-11: Most Important Bioabsorbable Stent Drawback, Latin American Responses, 2010
  • Figure 7-12: Most Important Drug-Eluting Stent Concern, Latin American Responses, 2010
  • Figure 7-13: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Latin American Responses, 2010
  • Figure 7-14: Preferred Brand of Stent-Graft, Latin American Responses, 2010
  • Figure 7-15: Most Important Construction Feature for Stent-Grafts, Latin American Responses, 2010
  • Figure 7-16: Most Important Design Feature for Next-Generation Stent-Grafts, Latin American Responses, 2010
  • Figure 7-17: Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts, Latin American Responses, 2010
  • Figure 7-18: Concerns about the Use of TAA Stent-Grafts, Latin American Responses, 2010
  • Figure 7-19: Most Promising Vulnerable Plaque Screening Technology, Latin American Responses, 2010
  • Figure 7-20: Most Promising Vulnerable Plaque Treatment Technology, Latin American Responses, 2010

ASIA-PACIFIC STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

  • Figure 8-1: Distribution of Survey Respondents by Geographic Region, Asia-Pacific Responses, 2010
  • Figure 8-2: Preferred Imaging Technology for DVT Diagnosis, Asia-Pacific Responses, 2010
  • Figure 8-3: Number and Type of Stents Placed per Month, Asia-Pacific Responses, 2010
  • Figure 8-4: Type of Medical Imaging Used for Endovascular Procedures, Asia-Pacific Responses, 2010
  • Figure 8-5: Type of Medical Imaging Used for Endovascular Procedures by Country, Asia-Pacific Responses, 2010
  • Figure 8-6: Bifurcated Stents and Their Use, Asia-Pacific Responses, 2010
  • Figure 8-7: Most Important Benefit When Using Bifurcated Stents, Asia-Pacific Responses, 2010
  • Figure 8-8: Drawbacks to the Use of Bifurcated Stents, Asia-Pacific Responses, 2010
  • Figure 8-9: Preferred Bifurcated Stent Alternatives, Asia-Pacific Responses, 2010
  • Figure 8-10: Bioabsorbable Stents and Their Use, Asia-Pacific Responses, 2010
  • Figure 8-11: Most Important Benefit When Using Bioabsorbable Stents, Asia-Pacific Responses, 2010
  • Figure 8-12: Most Important Bioabsorbable Stent Drawback, Asia-Pacific Responses, 2010
  • Figure 8-13: Most Important Drug-Eluting Stent Concern, Asia-Pacific Responses, 2010
  • Figure 8-14: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Asia-Pacific Responses, 2010
  • Figure 8-15: Preferred Brand of Stent-Graft, Asia-Pacific Responses, 2010
  • Figure 8-16: Most Important Construction Feature for Stent-Grafts, Asia-Pacific Responses, 2010
  • Figure 8-17: Most Important Design Feature for Next-Generation Stent-Grafts, Asia-Pacific Responses, 2010
  • Figure 8-18: Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts, Asia-Pacific Responses, 2010
  • Figure 8-19: Concerns about the Use of TAA Stent-Grafts, Asia-Pacific Responses, 2010
  • Figure 8-20: Most Promising Vulnerable Plaque Screening Technology, Asia-Pacific Responses, 2010
  • Figure 8-21: Most Promising Vulnerable Plaque Treatment Technology, Asia-Pacific Responses, 2010

MIDDLE EASTERN AND AFRICAN STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

  • Figure 9-1: Distribution of Survey Respondents by Geographic Region, Middle Eastern and African Responses, 2010
  • Figure 9-2: Number and Type of Stents Placed per Month, Middle Eastern and African Responses, 2010
  • Figure 9-3: Type of Medical Imaging Used for Endovascular Procedures, Middle Eastern and African Responses, 2010
  • Figure 9-4: Type of Medical Imaging Used for Endovascular Procedures by Country, Middle Eastern and African Responses, 2010
  • Figure 9-5: Bifurcated Stents and Their Use, Middle Eastern and African Responses, 2010
  • Figure 9-6: Most Important Benefit When Using Bifurcated Stents, Middle Eastern and African Responses, 2010
  • Figure 9-7: Drawbacks to the Use of Bifurcated Stents, Middle Eastern and African Responses, 2010
  • Figure 9-8: Preferred Bifurcated Stent Alternatives, Middle Eastern and African Responses, 2010
  • Figure 9-9: Bioabsorbable Stents and Their Use, Middle Eastern and African Responses, 2010
  • Figure 9-10: Most Important Benefit When Using Bioabsorbable Stents, Middle Eastern and African Responses, 2010
  • Figure 9-11: Most Important Bioabsorbable Stent Drawback, Middle Eastern and African Responses, 2010
  • Figure 9-12: Most Important Drug-Eluting Stent Concern, Middle Eastern and African Responses, 2010
  • Figure 9-13: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Middle Eastern and African Responses, 2010
  • Figure 9-14: Preferred Brand of Stent-Graft, Middle Eastern and African Responses, 2010
  • Figure 9-15: Most Important Construction Feature for Stent-Grafts, Middle Eastern and African Responses, 2010
  • Figure 9-16: Most Important Design Feature for Next-Generation Stent-Grafts, Middle Eastern and African Responses, 2010
  • Figure 9-17: Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts, Middle Eastern and African Responses, 2010
  • Figure 9-18: Concerns about the Use of TAA Stent-Grafts, Middle Eastern and African Responses, 2010
  • Figure 9-19: Most Promising Vulnerable Plaque Screening Technology, Middle Eastern and African Responses, 2010
  • Figure 9-20: Most Promising Vulnerable Plaque Treatment Technology, Middle Eastern and African Responses, 2010

ABBREVIATIONS

APPENDIX

  • Figure 11-1: Geographic Distribution of Responses, U.S., 2010
  • Figure 11-2: Geographic Distribution of Responses, European Region, 2010
  • Figure 11-3: Geographic Distribution of Responses, Latin American Region, 2010
  • Figure 11-4: Geographic Distribution of Responses, Asia-Pacific Region, 2010
  • Figure 11-5: Geographic Distribution of Responses, Middle Eastern and African Region, 2010

LIST OF CHARTS

EXECUTIVE SUMMARY

  • Chart 1-1: Respondent Location by Geographic Region, Global Responses, Stents, Stent-Grafts and Vulnerable Plaque, 2010
  • Chart 1-2: Average Number of Stents Placed per Month by Respondents, Global Responses, Stents, Stent-Grafts and Vulnerable Plaque, 2010
  • Chart 1-3: Bifurcated Stent Alternatives, Global Responses, Stents, Stent-Grafts and Vulnerable Plaque, 2010
  • Chart 1-4: Vulnerable Plaque Screening Technology, Global Responses, Stents, Stent-Grafts and Vulnerable Plaque, 2010
  • Chart 1-5: Most Promising Vulnerable Plaque Treatment, U.S. Respondents, Stents, Stent-Grafts and Vulnerable Plaque, 2010

SURVEY HIGHLIGHTS

RESEARCH METHODOLOGY

GLOBAL STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

  • Chart 4-1: Respondent Specialty, Global Responses, 2010
  • Chart 4-2: Average Stents Placed per Respondent, Global Responses, 2010
  • Chart 4-3: Imaging Technology Preferences, Percentage of Total, Global Responses, 2010
  • Chart 4-4: Bifurcated Stents and Their Use, U.S. Responses, 2010
  • Chart 4-5: Bifurcated Stents and Their Use, European Responses, 2010
  • Chart 4-6: Bifurcated Stents and Their Use, Latin American Responses, 2010
  • Chart 4-7: Bifurcated Stents and Their Use, Asia-Pacific Responses, 2010
  • Chart 4-8: Bifurcated Stents and Their Use, Middle Eastern and African Responses, 2010
  • Chart 4-9: Most Important Bifurcated Stent Benefit, Global Responses, 2010
  • Chart 4-10: Most Important Bifurcated Stent Drawback, Global Responses, 2010
  • Chart 4-11: Preferred Bifurcated Stent Alternatives, U.S. Responses, 2010
  • Chart 4-12: Preferred Bifurcated Stent Alternatives, European Responses, 2010
  • Chart 4-13: Preferred Bifurcated Stent Alternatives, Latin American Responses, 2010
  • Chart 4-14: Preferred Bifurcated Stent Alternatives, Asia-Pacific Responses, 2010
  • Chart 4-15: Preferred Bifurcated Stent Alternatives, Middle Eastern and African Responses, 2010
  • Chart 4-16: Bioabsorbable Stents and Their Use, U.S. Responses, 2010
  • Chart 4-17: Bioabsorbable Stents and Their Use, European Responses, 2010
  • Chart 4-18: Bioabsorbable Stents and Their Use, Latin American Responses, 2010
  • Chart 4-19: Bioabsorbable Stents and Their Use, Asia-Pacific Responses, 2010
  • Chart 4-20: Bioabsorbable Stents and Their Use, Middle Eastern and African Responses, 2010
  • Chart 4-21: Most Important Bioabsorbable Stent Benefit, Global Responses, 2010
  • Chart 4-22: Most Important Bioabsorbable Stent Drawback, Global Responses, 2010
  • Chart 4-23: Most Important Drug-Eluting Stent Concern, Global Responses, 2010
  • Chart 4-24: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, U.S. Responses, 2010
  • Chart 4-25: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, European Responses, 2010
  • Chart 4-26: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Latin American Responses, 2010
  • Chart 4-27: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Asia-Pacific Responses, 2010
  • Chart 4-28: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Middle Eastern and African Responses, 2010
  • Chart 4-29: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, U.S. Responses, 2010
  • Chart 4-30: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, European Responses, 2010
  • Chart 4-31: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Latin American Responses, 2010
  • Chart 4-32: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Asia-Pacific Responses, 2010
  • Chart 4-33: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Middle Eastern and African Responses, 2010
  • Chart 4-34: Most Important Construction Feature for Stent-Grafts, Global Responses, 2010
  • Chart 4-35: Most Important Design Feature for Next-Generation Stent-Grafts, Global Responses, 2010
  • Chart 4-36: The Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts, Global Responses, 2010
  • Chart 4-37: Concerns about the Use of TAA Stent-Grafts, Global Responses, 2010
  • Chart 4-38: Most Promising Vulnerable Plaque Screening Technology, Global Responses, 2010
  • Chart 4-39: Most Promising Vulnerable Plaque Treatment Technology, Global Responses, 2010

U.S. STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

  • Chart 5-1: Total Number of Stents Placed per Month, U.S. Responses, 2010
  • Chart 5-2: Number of Coronary Stents Placed per Month, U.S. Responses, 2010
  • Chart 5-3: Number of Peripheral Stents Placed per Month, U.S. Responses, 2010
  • Chart 5-4: Type of Medical Imaging Used for Endovascular Procedures, U.S. Responses, 2010
  • Chart 5-5: Bifurcated Stents and Their Use, U.S. Responses, 201
  • Chart 5-6: Most Important Benefit When Using Bifurcated Stents, U.S. Responses, 2010
  • Chart 5-7: Drawbacks to the Use of Bifurcated Stents, U.S. Responses, 2010
  • Chart 5-8: Preferred Bifurcated Stent Alternatives, U.S. Responses, 2010
  • Chart 5-9: Preferred Bifurcated Stent Alternatives by Specialty, U.S. Responses, 2010
  • Chart 5-10: Bioabsorbable Stents and Their Use, U.S. Responses, 2010
  • Chart 5-11: Most Important Benefit When Using Bioabsorbable Stents, U.S. Responses, 2010
  • Chart 5-12: Most Important Bioabsorbable Stent Drawback, U.S. Responses, 2010
  • Chart 5-13: Most Important Drug-Eluting Stent Concern, U.S. Responses, 2010
  • Chart 5-14: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, U.S. Responses, 2010
  • Chart 5-15: Most Effective Drug-Eluting Stent Drug for Combating Restenosis by Specialty, U.S. Responses, 2010
  • Chart 5-16: Preferred Brand of Stent-Graft, U.S. Responses, 2010
  • Chart 5-17: Most Important Construction Feature for Stent-Grafts, U.S. Responses, 2010
  • Chart 5-18: Most Important Design Feature for Next-Generation Stent-Grafts, U.S. Responses, 2010
  • Chart 5-19: Use of TAA Stent-Grafts, U.S. Responses, 2010
  • Chart 5-20: Concerns about the Use of TAA Stent-Grafts, U.S. Responses, 2010
  • Chart 5-21: Most Promising Vulnerable Plaque Screening Technology, U.S. Responses, 2010
  • Chart 5-22: Most Promising Vulnerable Plaque Screening Technology by Specialty, U.S. Responses, 2010
  • Chart 5-23: Most Promising Vulnerable Plaque Treatment Technology, U.S. Responses, 2010
  • Chart 5-24: Most Promising Vulnerable Plaque Treatment Technology by Specialty, U.S. Responses, 2010

EUROPEAN STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

  • Chart 6-1: Total Number of Stents Placed per Month, European Responses, 2010
  • Chart 6-2: Number of Coronary Stents Placed per Month, European Responses, 2010
  • Chart 6-3: Number of Peripheral Stents Placed per Month, European Responses, 2010
  • Chart 6-4: Type of Medical Imaging Used for Endovascular Procedures, European Responses, 2010
  • Chart 6-5: Bifurcated Stents and Their Use, European Responses, 2010
  • Chart 6-6: Most Important Benefit When Using Bifurcated Stents, European Responses, 2010
  • Chart 6-7: Drawbacks to the Use of Bifurcated Stents, European Responses, 2010
  • Chart 6-8: Preferred Bifurcated Stent Alternatives, European Responses, 2010
  • Chart 6-9: Preferred Bifurcated Stent Alternatives by Specialty, European Responses, 2010
  • Chart 6-10: Bioabsorbable Stents and Their Use, European Responses, 2010
  • Chart 6-11: Most Important Benefit When Using Bioabsorbable Stents, European Responses, 2010
  • Chart 6-12: Most Important Bioabsorbable Stent Drawback, European Responses, 2010
  • Chart 6-13: Most Important Drug-Eluting Stent Concern, European Responses, 2010
  • Chart 6-14: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, European Responses, 2010
  • Chart 6-15: Most Effective Drug-Eluting Stent Drug for Combating Restenosis by Specialty, European Responses, 2010
  • Chart 6-16: Preferred Brand of Stent-Graft, European Responses, 2010
  • Chart 6-17: Most Important Construction Feature for Stent-Grafts, European Responses, 2010
  • Chart 6-18: Most Important Design Feature for Next-Generation Stent-Grafts, European Responses, 2010
  • Chart 6-19: Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts, European Responses, 2010
  • Chart 6-20: Concerns about the Use of TAA Stent-Grafts, European Responses, 2010
  • Chart 6-21: Most Promising Vulnerable Plaque Screening Technology, European Responses, 2010
  • Chart 6-22: Most Promising Vulnerable Plaque Screening Technology by Specialty, European Responses, 2010
  • Chart 6-23: Most Promising Vulnerable Plaque Treatment Technology, European Responses, 2010

LATIN AMERICAN STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

  • Chart 7-1: Total Number of Stents Placed per Month, Latin American Responses, 2010
  • Chart 7-2: Number of Coronary Stents Placed per Month, Latin American Responses, 2010
  • Chart 7-3: Number of Peripheral Stents Placed per Month, Latin American Responses, 2010
  • Chart 7-4: Type of Medical Imaging Used for Endovascular Procedures, Latin American Responses, 2010
  • Chart 7-5: Type of Medical Imaging Used for Endovascular Procedures by Country, Latin American Responses, 2010
  • Chart 7-6: Bifurcated Stents and Their Use, Latin American Responses, 2010
  • Chart 7-7: Most Important Benefit When Using Bifurcated Stents, Latin American Responses, 2010
  • Chart 7-8: Drawbacks to the Use of Bifurcated Stents, Latin American Responses, 2010
  • Chart 7-9: Preferred Bifurcated Stent Alternatives, Latin American Responses, 2010
  • Chart 7-10: Bioabsorbable Stents and Their Use, Latin American Responses, 2010
  • Chart 7-11: Most Important Benefit When Using Bioabsorbable Stents, Latin American Responses, 2010
  • Chart 7-12: Most Important Bioabsorbable Stent Drawback, Latin American Responses, 2010
  • Chart 7-13: Most Important Drug-Eluting Stent Concern, Latin American Responses, 2010
  • Chart 7-14: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Latin American Responses, 2010
  • Chart 7-15: Preferred Brand of Stent-Graft, Latin American Responses, 2010
  • Chart 7-16: Most Important Construction Feature for Stent-Grafts, Latin American Responses, 2010
  • Chart 7-17: Most Important Design Feature for Next-Generation Stent-Grafts, Latin American Responses, 2010
  • Chart 7-18: Concerns about the Use of TAA Stent-Grafts, Latin American Responses, 2010
  • Chart 7-19: Most Promising Vulnerable Plaque Screening Technology, Latin American Responses, 2010
  • Chart 7-20: Most Promising Vulnerable Plaque Treatment Technology, Latin American Responses, 2010

ASIA-PACIFIC STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

  • Chart 8-1: Total Number of Stents Placed per Month, Asia-Pacific Responses, 2010
  • Chart 8-2: Number of Coronary Stents Placed per Month, Asia-Pacific Responses, 2010
  • Chart 8-3: Number of Peripheral Stents Placed per Month, Asia-Pacific Responses, 2010
  • Chart 8-4: Type of Medical Imaging Used for Endovascular Procedures, Asia-Pacific Responses, 2010
  • Chart 8-5: Bifurcated Stents and Their Use, Asia-Pacific Responses, 2010
  • Chart 8-6: Most Important Benefit When Using Bifurcated Stents, Asia-Pacific Responses, 2010
  • Chart 8-7: Drawbacks to the Use of Bifurcated Stents, Asia-Pacific Responses, 2010
  • Chart 8-8: Preferred Bifurcated Stent Alternatives, Asia-Pacific Responses, 2010
  • Chart 8-9: Bioabsorbable Stents and Their Use, Asia-Pacific Responses, 2010
  • Chart 8-10: Most Important Benefit When Using Bioabsorbable Stents, Asia-Pacific Responses, 2010
  • Chart 8-11: Most Important Bioabsorbable Stent Drawback, Asia-Pacific Responses, 2010
  • Chart 8-12: Most Important Drug-Eluting Stent Concern, Asia-Pacific Responses, 2010
  • Chart 8-13: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Asia-Pacific Responses, 2010
  • Chart 8-14: Preferred Brand of Stent-Graft, Asia-Pacific Responses, 2010
  • Chart 8-15: Most Important Construction Feature for Stent-Grafts, Asia-Pacific Responses, 2010
  • Chart 8-16: Most Important Design Feature for Next-Generation Stent-Grafts, Asia-Pacific Responses, 2010
  • Chart 8-17: Concerns about the Use of TAA Stent-Grafts, Asia-Pacific Responses, 2010
  • Chart 8-18: Most Promising Vulnerable Plaque Screening Technology, Asia-Pacific Responses, 2010
  • Chart 8-19: Most Promising Vulnerable Plaque Treatment Technology, Asia-Pacific Responses, 2010

MIDDLE EASTERN AND AFRICAN STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE

  • Chart 9-1: Total Number of Stents Placed per Month, Middle Eastern and African Responses, 2010
  • Chart 9-2: Number of Coronary Stents Placed per Month, Middle Eastern and African Responses, 2010
  • Chart 9-3: Number of Peripheral Stents Placed per Month, Middle Eastern and African Responses, 2010
  • Chart 9-4: Type of Medical Imaging Used for Endovascular Procedures, Middle Eastern and African Responses, 2010
  • Chart 9-5: Bifurcated Stents and Their Use, Middle Eastern and African Responses, 2010
  • Chart 9-6: Most Important Benefit When Using Bifurcated Stents, Middle Eastern and African Responses, 2010
  • Chart 9-7: Drawbacks to the Use of Bifurcated Stents, Middle Eastern and African Responses, 2010
  • Chart 9-8: Preferred Bifurcated Stent Alternatives, Middle Eastern and African Responses, 2010
  • Chart 9-9: Bioabsorbable Stents and Their Use, Middle Eastern and African Responses, 2010
  • Chart 9-10: Most Important Benefit When Using Bioabsorbable Stents, Middle Eastern and African Responses, 2010
  • Chart 9-11: Most Important Bioabsorbable Stent Drawback, Middle Eastern and African Responses, 2010
  • Chart 9-12: Most Important Drug-Eluting Stent Concern, Middle Eastern and African Responses, 2010
  • Chart 9-13: Most Effective Drug-Eluting Stent Drug for Combating Restenosis, Middle Eastern and African Responses, 2010
  • Chart 9-14: Preferred Brand of Stent-Graft, Middle Eastern and African Responses, 2010
  • Chart 9-15: Most Important Construction Feature for Stent-Grafts, Middle Eastern and African Responses, 2010
  • Chart 9-16: Most Important Design Feature for Next-Generation Stent-Grafts, Middle Eastern and African Responses, 2010
  • Chart 9-17: Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts, Middle Eastern and African Responses, 2010
  • Chart 9-18: Concerns about the Use of TAA Stent-Grafts, Middle Eastern and African Responses, 2010
  • Chart 9-19: Most Promising Vulnerable Plaque Screening Technology, Middle Eastern and African Responses, 2010
  • Chart 9-20: Most Promising Vulnerable Plaque Treatment Technology, Middle Eastern and African Responses, 2010

ABBREVIATIONS

APPENDIX

Published By: iData Research
Product Code: iData Research1191


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:


Connect With Us
link
Follow ReportsnReports.com on Twitter
ReportsnReports.com RSS
ReportsnReports.com blog
ReportsnReports.com on google plus
Email: sales@reportsandreports.com Call : + 1 888 391 5441
Subscription Option

Using our subscription option, you get access to market research reports and industry data of Medical Devices market as per your needs. Get the best of Medical Devices research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

Live Chat
Live Chat by Comm100